Involvement of complement components in renal disease

Current Opinion in Nephrology and Hypertension

Volumn 6, Issue 2, 1997, Pages 120-127

  Johnson, Richard J ^a  

^a BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; MONOCLONAL ANTIBODY; SNAKE VENOM;

HUMAN; KIDNEY DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 0030982310     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199703000-00003     Document Type: Review

References (51)

1. Johnson RJ: Immunology and the complement system. In Biomaterials Science. Edited by Rattner BD, Hoffman AS, Schoen FJ, Lemons JE. San Diego, California: Academic Press; 1996:173-188.
2. Hebert LA, Cosio FG, Birmingham DJ: The role of the complement system in renal injury. Semin Nephrol 1992, 12:408-427.
3. Colten HR, Rosen FS: Complement deficiencies. In Annual Reviews of Immunology, vol 10. Edited by Paul WE, Fathmen CG, Metzger H, Palo Alto, California: Annual Reviews Inc.; 1992:809-834.
4. Lhotta K, Neurnhäuserer M, Solder B, Uring-Lambert B, Würzner R, Rumpelt HJ, König P: Recurrent hematuria: a novel clinical presentation of hereditary complete complement C4 deficiency. Am J Kidney Dis 1996, 27:424-427.
5. Jin DK, Kohsaka T, Koo JW, Ha IS, Cheong HI, Choi Y: Complement 4 locus II gene deletion and DQA1*0301 gene: genetic risk factors for IgA nephropathy and Henoch-Schönlein nephritis. Nephron 1996, 73:390-395.
6. Jansen JH, Høgåsen K, Grøndahl AM: Porcine membranoproliferative glomerulonephritis type II: an autosomal recessive deficiency of factor H. Vet Record 1995, 137:240-244.
7. Vogt BA, Wyatt RJ, Burke BA, Simonton SC, Kashtan CE: Inherited factor H deficiency and collagen type III glomerulopathy. Pediatr Nephrol 1995, 9:11-15.
8. Høgåsen K, Jansen JH, Mollnes TE, Hovdenes J, Harboe M: Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency. J Clin Invest 1995, 95:1054-1061.
9. Pinchette V, Quérin S, Schürch W, Brun G, Lehner-Netsch G, Delâge JM: Familial hemolytic-uremic syndrome and homozygous factor H deficiency. Am J Kidney Dis 1994, 24:936-941.
10. Nishikage H, Nomura A, Yoshida F, Matsuo S: The role of a complement regulatory protein in rat mesangial glomerulonephritis. J Am Soc Nephrol 1995, 6:234-242.
11. Hatanaka Y, Yuzawa Y, Hishikawa K, Fukatsu A, Okada N, Okada H, Mizuno M, Matsuo S: Role of a rat membrane inhibitor of complement in anti-basement membrane antibody-induced renal injury. Kidney Int 1995, 48:1728-1737. This work demonstrated the importance of complement regulatory proteins in regulating vascular permeability and the progression of inflammatory injury to tubulointerstitial structures.
12. Saunders JR, Aminian A, McRae JL, O'Farrell KA, Adam WR, Murphy BF: Clusterin depletion enhances immune glomerular injury in the isolated perfused kidney. Kidney Int 1994, 45:817-827.
13. Matsuo S, Nishikage H, Yoshida F, Nomura A, Piddlesden SJ, Morgan BP: Role of CD59 in experimental glomerulonephritis in rats. Kidney Int 1994, 46:191-200.
14. Quigg RJ, Morgan BP, Holers VM, Adler S, Sneed AR III, Lo CF: Complement regulation in the rat glomerulus: Cryy and CD59 regulate complement in glomerular mesangial and endothelial cells. Kidney Int 1995, 48:412-421. This paper investigated the relative contribution of rat Crry (the rat membrane cofactor protein/decay accelerating factor analog) and CD59 in protecting endothelial cells and masangial cells for complement mediated cytotoxicity. They showed that Cryy played a more prominent role in controlling alternative pathway mediated events.
15. Brandt J, Pippin J, Schulze M, Hansch GM, Alpers CE, Johnson RJ, Gorson K, Couser WG: Role of the complement membrane attack complex (C5b-9) in mediating experimental mesangioproliferative glomerulonephritis. Kidney Int 1996, 49:335-343. These authors present evidence that suggest that C5b-9 (MAC) plays a significant role in causing the damage induced by complement in the antithymocyte serum model. They used the PVG C6-rat model.
16. Leenaerts PL, Hall BM, Van Damme BJ, Daha MR, Vanrenterghem YF: Active Heymann nephritis in complement component C6 deficient rats. Kidney Int 1995, 47:1604-1614.
17. Scandrett AL, Kissane J, Lefkowith JB: Acute inflammation is the harbinger of glomerulosclerosis in anti-glomerular basement membrane nephritis. Am J Physiol 1995, 268:F258-F265.
18. Couser WG, Johnson RJ, Young BA, Yeh CG, Toth CA, Rudolph AR: The effects of soluble recombinant complement receptor 1 on complement-mediated experimental glomerulonephritis. J Am Soc Nephrol 1995, 5:1888-1894. This work showed that sCR1 can significantly mitigate complementmediated tissue damage and renal pathology in several model systems of GN. These results may have therapeutic implications since sCR1 is now in clinical trials to evaluate its anti-inflammatory potential.
19. Kahn TN, Sinniah R: Role of complement in renal tubular damage. Histopathology 1995, 26:351-356.
20. Alexopoulos A, Papaghianni A, Papadimitriou M: The pathogenic significance of C5b-9 in IgA nephropathy. Nephrol Dial Transplant 1995, 10:1166-1172.
21. Kon SP, Coupes B, Short CD, Solomon LR, Raftery MJ, Mallick NP, Brenchley PE: Urinary C5b-9 excretion and clinical course in idiopathic human membranous nephropathy. Kidney Int 1995, 48:1953-1958. This study demonstrated a relationaship between clinical outcome and urinary SC5b-9 levels. Elevated SC5b-9 levels were correlated positively with poor prognosis and thus may be a dynamic marker of ongoing tissue injury and offer a means of monitoring the effectiveness of immunosupressive therapy.
22. Lehto T, Honkanen E, Teppo A-M, Meri S: Urinary excretion of protectin (CD59), complement sC5b-9 and cytokines in membranous glomerulonephritis. Kidney Int 1995, 47:1403-1411.
23. Van den Dobbelsteen MEA, Van der Woude FJ, Schoeijers WEM, Klar-Mohamad N, van Es LA, Daha MR: Both IgG and C1q-receptors play a role in the enhanced binding of IgG complexes to human mesangial cells. J Am Soc Nephrol 1996, 7:573-581.
24. Lozada C, Levin RI, Huie M, Hirschhorn R, Naime D, Whitlow M, Recht PA, Golden B, Cronstein BN: Identification of C1q as the heat-labile serum cofactor required for immune complexes to stimulate endothelial expression of the adhesion molecules E-selectin and intercellular and vascular cell adhesion molecules 1. Proc Natl Acad Sci U S A 1995, 92:8378-8382.
25. 2 in glomerular epithelial cells. Am J Physiol 1995, 269:F739-F749.
26. Welch TR, Beischel LS, Frenzke M, Witte D: Regulated expression of complement factor B in the human kidney. Kidney Int 1996, 50:521-525.
27. Oren R, Laufer J, Goldberg I, Kopolovic J, Waldherr R, Passwell JH: C3, C4, factor B, and HLA-DRα mRNA expression in renal biopsy specimens from patients with IgA nephropathy. Immunology 1995, 86:575-583.
28. Moutabarrik A, Nakanishi I, Matsumoto M, Zaid D, Seya T: Human glomerular epithelial cells synthesize and secrete the third component of complement Nephron 1995, 70:55-61.
29. Johnson RJ: Complement activation during extracorporeal therapy: biochemistry, cell biology and clinical relevence. Nephrol Dial Transplant 1994, 9:36-45.
30. Thylén P, Fernvik E, Lundahl J, Hed J, Jacobson SH: Modulation of CD11b/CD18 on monocytes and granulocytes following hemodialysis membrane interaction in vitro, Int J Artif Organs 1996, 19:156-163.
31. Johnson RJ, Burhop KE, Van Epps DE: Infusion of ovine CSa into sheep mimics the inflammatory response of hemodialysis. J Lab Clin Med 1996, 127:456-469. This work showed that infusion of purified C5a into sheep can mimic the inflammatory response induced by complement activating dialysis membranes, demonstrating that C5a is the relevant mediator in this setting.
32. Tielemans CL, Delville J-PC, Husson CP, Madhoun P, Lambrechts AM, Goldman M, Vanherweghem J-L: Adhesion molecules and leukocyte common antigen on monocytes and granulocytes during hemodialysis. Clinical Nephrol 1993, 39:158-163.
33. Himmerlfarb J, Zaoui P, Hakim R: Modulation of granulocyte LAM-1 and MAC-1 during dialysis: A prospective, randomized controlled trial. Kidney Int 1992, 41:388-395.
34. Alverez V, Pulido R, Campanero MR, Paraiso V, De Landazuri MO, Sanchez-Madrid F: Differentially regulated cell surface expression of leukocyte adhesion receptors on neutrophils. Kidney Int 1991, 41:899-905.
35. Kaupke CJ, Zhang J, Cesario T, Yousefi S, Akeel N, Vaziri ND: Effect of hemodialysis on leukocyte adhesion receptor expression. Am J Kidney Dis 1996, 27:244-252.
36. Marchant A, Tielemans C, Husson C, Gastaldello K, Schurmans T, De Groot D, Duchow J, Vanherweghem JL, Goldman M: Cuprophane hemodialysis induces upregulation of LPS receptor (CD14) on monocytes: role of complement activation. Nephrol Dial Transplant 1996, 11:657-662.
37. Skroeder NR, Kjellstrand P, Holmquist B, Nilsson U, Jacobson SH: Increased amounts of C3a and the terminal complement complex at high dialysis blood-flow: the relation with dialysis efficiency. Nephron 1996, 72:523-529.
38. Skroeder NR, Kjellstrand P, Holmquist B, Kjellstrand CM, Jacobson SH: On complement net generation in fast hemodialysis: are high blood flow rates bioincompatible? Am J Kidney Dis 1995, 25:896-903.
39. Parker TF, Wingard RL, Husni L, Ikizler TA, Parker RA, Hakim RM: Effect of the membrane biocompatibility on nutritional parameters in chronic hemodialysis patients. Kidney Int 1996, 49:551-556.
40. Hakim RM, Held PJ, Stannard DC, Wolfe RA, Port FK, Daugirdas JT, Agodoa L: Effect of the dialysis membrane on mortality of chronic hemodialysis patients. Kidney Int 1996, 50:566-570.
41. Lawson JH, Platt JL: Molecular barriers to xenotransplantation. Transplantation 1996, 62:303-310. This is a well written review on xenotransplantation and the current issues in this area.
42. Bach FH, Robson SC, Winkler H, Ferran C, Stuhlmeirer KM, Wrighton CJ, Hancock WW: Barriers to xenotransplantation. Nature Med 1995, 1:869-873.
43. Watier H, Guillaumin J-M, Piller F, Lacord M, Thibault G, Lebranchu Y, Monsigny M, Bardos P: Removal of terminal α-galactosyl residues from xenogeneic porcine endothelial cells. Transplantation 1996, 62:105-113.
44. Galili U, Matta KL: Inhibition of anti-gal IgG binding to porcine endothelial cells by synthetic oligosaccharides. Transplantation 1996, 62:256-262.
45. Cairns T, Lee J, Goldberg L, Cook T, Simpson P, Spackman D, Palmer A, Taube D: Inhibition of the pig to human xenograft reaction using soluble galα1-3gal and galα1-3galβ1-4glcNac. Transplantation 1995, 60:1202-1207.
46. Candinas D, Lesnikoski B-A, Robson SC, Miyatake T, Scesney SM, Marsh HC Jr, Ryan US, Dalmasso AP, Hancock WW, Bach FH: Effect of repetitive high-dose treatment with soluble complement receptor type 1 and cobra venom factor on discordant xenograft survival. Transplantation 1996, 62:336-342.
47. Kroshus TJ, Rollins SA, Dalmasso AP, Elliott EA, Matis LA, Squinto SP, Bolman RM III: Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation. Transplantation 1995, 60:1194-1202. These authors described an anti-C5 monoclonal antibody that effectively inhibits C5 conversion and thus limited HAR in this model system. As with sCR1, this monoclonal may have therapeutic potential in the renal setting.
48. Kroshus TJ, Bolman RM III, Dalmasso AP, Rollins SA, Guilmette ER, Williams BL, Squinto SP, Fodor WL: Expression of human CD59 in transgenic pig organs enhances organ survival in an ex vivo xenogeneic perfusion model. Transplantation 1996, 61:1513-1521.
49. Diamond LE, McCurry KR, Martin MJ, McClellan SB, Oldham ER, Platt JL, Logan JS: Characterization of transgenic pigs expressing functionally active human CD59 on cardiac endothelium. Transplantation 1996, 61:1241-1249.
50. Kooyman DL, Byrne GW, McClellan S, Nielsen D, Tone M, Waldman H, Coffman TM, McCurry KR, Platt JL, Logan JS: In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium. Science 1995, 269:89-92.
51. Nangaku M, Meek RL, Pippin J, Gordon KL, Morgan BP, Johnson RJ, Couser WG: Transfected CD59 protects mesangial cells from injury induced by antibody and complement Kidney Int 1996, 50:257-266. This paper demonstrated the potential effectiveness of transfecting CD59 into mesangial cells, which overexpressed the protein and protected the cells from complement attack. This work represents the application of gene therapy technology to treat renal disease and thus may be the first step in a long path to achieving clinically useful therapy with this technology.